Is Transrectal Ultrasonography Needed to Rule Out Prostatic Cancer with Normal Findings at Digital Rectal Examination and Normal Serum Prostate-Specific Antigen?

1993 ◽  
Vol 24 (4) ◽  
pp. 474-478 ◽  
Author(s):  
R. Simak ◽  
M. Eisenmenger ◽  
A. Hainz ◽  
C. Kratzik ◽  
M. Marberger
Keyword(s):  
Prostate Specific Antigen ◽  
Prostatic Cancer ◽  
Specific Antigen ◽  
Digital Rectal Examination ◽  
Normal Serum ◽  
Transrectal Ultrasonography ◽  
Rectal Examination ◽  
Serum Prostate Specific Antigen ◽  
Rule Out

Comparing Two Modalities of Screening for Prostate Cancer: Digital Rectal Examination + Transrectal Ultrasonography Vs. Prostate-Specific Antigen

1995 ◽  
Vol 81 (4) ◽  
pp. 225-229 ◽  
Author(s):  
Stefano Ciatto ◽  
Rita Bonardi ◽  
Antonia Mazzotta ◽  
Claudio Lombardi ◽  
Roberto Santoni ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Early Detection ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Digital Rectal Examination ◽  
Transrectal Ultrasonography ◽  
Attendance Rate ◽  
Predictive Values ◽  
Rectal Examination ◽  
Biopsy Rate

Aims and background To evaluate the performance and feasibility of screening for prostate cancer by comparing screening modalities. Methods Prospective study of two comparable cohorts of healthy resident males aged 60 to 75 years. Screening attenders in the two invited cohorts were screened either by digital rectal examination (DRE) and transrectal ultrasonography (TRUS), or by serum prostate-specific antigen determination (PSA: cutoff 4 ng/ml). Attendance and biopsy rates, predictive values, prevalence of screen-detected cancers, as well as screening costs were determined, and the efficiency of the two screening modalities was compared. Results 1425 subjects were screened by DRE + TRUS. Attendance rate was 33.7%, the biopsy rate was 2.7%, and the prevalence of detected cancers was 1.82%. A total of 1315 subjects was screened by PSA. Attendance rate was 66.9%, the biopsy rate was 2.8%, and the prevalence of detected cancers was 1.67%. Screen-detected cancer stage was more favorable than observed in clinical practice, and early detection was evident, with the prevalence/incidence ratio higher than 10:1 in both programs. The cost per subject screened was about 34,000 Lire for DRE + TRSU and about 30,000 Lire for PSA program. Conclusions The study confirms that early detection of prostate cancer is possible and that screening is practically feasible. Both screening modalities achieved comparable results as regards early detection, but screening by PSA had a higher compliance and lower costs. PSA seems the ideal test to be used in prospective controlled studies aimed at demonstrating screening efficacy.

Should Men with Serum Prostate-Specific Antigen ≤4 ng/ml and Normal Digital Rectal Examination Undergo a Prostate Biopsy?

Oncology ◽  
2006 ◽  
Vol 70 (2) ◽  
pp. 81-89 ◽  
Author(s):  
Pietro Pepe ◽  
Paolo Panella ◽  
Letterio D’Arrigo ◽  
Francesco Savoca ◽  
Michele Pennisi ◽  
...  
Keyword(s):  
Prostate Specific Antigen ◽  
Prostate Biopsy ◽  
Specific Antigen ◽  
Digital Rectal Examination ◽  
Rectal Examination ◽  
Serum Prostate Specific Antigen
Sign in / Sign up

Export Citation Format

Share Document